Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients.
Randomized controlled trials conducted since 2000 have shown that new antibacterial and antifungal agents may reduce the frequency of kidney injury in selected groups of critically ill patients, yet it is unclear whether these benefits translate to the clinical setting. The aim of the present study was to evaluate longitudinally the successive routine implementation of new antimicrobial agents (caspofungin, voriconazole, linezolid) after February 2002 and the association of these agents with the frequency of mechanical renal replacement therapy in postsurgical critically ill patients at risk of severe kidney failure. A retrospective, observational cohort study was performed using data collected prospectively from 1 March 1993 through 28 February 2005. A cohort of 2,123 consecutive cases who required intensive care therapy for more than 2 days was analysed. A statistically significant decrease in the frequency of renal replacement therapy was observed in the later years of the study. After adjustment for relevant covariates, treatment with new antimicrobial agents after February 2002 was identified as an independent factor linked with a reduced risk of severe kidney failure (odds ratio 0.244; 95% confidence interval 0.136-0.439). Thus, the implementation of new antimicrobial agents with reduced or no nephrotoxicity into routine care of critically ill surgical patients is associated with a reduced need for renal replacement therapy.
Eichhorn
M E
ME
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians University Munich, Marchioninistr 15, 81377, Munich, Germany.
Wolf
H
H
Küchenhoff
H
H
Joka
M
M
Jauch
K-W
KW
Hartl
W H
WH
D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077336:Caspofungin; D015331:Cohort Studies; D016638:Critical Illness; D054714:Echinocandins; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D000069349:Linezolid; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000627:therapeutic use; D011183:Postoperative Complications; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced*; D017582:Renal Replacement Therapy / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D065819:Voriconazole
D000081:Acetamides; D000890:Anti-Infective Agents; D054714:Echinocandins; D055666:Lipopeptides; D023303:Oxazolidinones; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D000069349:Linezolid; D065819:Voriconazole